The landscape of cervical cancer screening is evolving with the FDA’s recent approval of the Teal Wand, a self-collection device for HPV testing. This innovative tool allows individuals to collect samples at home, eliminating the need for a speculum exam or a visit to a healthcare provider. The sample is then sent to a lab for analysis.

Cervical cancer screening is crucial for early detection, often identifying precancerous changes before they develop into cancer.however,screening rates have been declining,prompting experts to explore alternative approaches like at-home testing to improve participation.

Understanding Cervical Cancer screening

Over the past few decades, advancements in understanding the causes of cervical cancer and the development of improved testing methods have led to significant changes in screening practices. Currently, two primary screening tests are available: the PAP Test and the HPV test.

The PAP Test, also known as cytology, involves collecting cells from the surface of the cervix and examining them under a microscope to detect cancerous or precancerous abnormalities. The HPV test, on the other hand, identifies the presence of high-risk types of the human papillomavirus, notably types 16 and 18, which are responsible for approximately 90% of all cervical cancer cases.

Cervical cancer screening is crucial for early detection, often identifying precancerous changes before they develop into cancer.

Current guidelines recommend that individuals begin undergoing PAP Tests at age 21, with testing every three years if results are normal. For those between the ages of 30 and 65, screening options include a PAP Test alone, an HPV test alone, or a combination of both. The frequency of testing varies depending on the specific tests performed and the individual’s history of normal results, but moast people require screening every three to five years until age 65.

The Teal Wand: A New Era of Self-Collection

Traditionally, cervical cancer screening involved a clinician using a speculum to visualize the cervix and collect cells using a swab, brush, or spatula. While generally painless, this process requires an office visit, and many individuals find the speculum exam uncomfortable.

The FDA approved the first self-collected HPV test last year. While still administered in a healthcare setting, patients could collect their own samples using a provided kit and private space. The approval of the Teal Wand expands access to at-home screenings.

The Teal Wand features a one-handed design with a handle, a sponge at the top, and a dial at the bottom for spinning the sponge. During self-collection, individuals insert the wand into the vagina until they feel slight resistance and then use the dial to rotate the sponge, collecting cells from the upper portion of the vagina. The sponge is then detached and sent to a lab for analysis.

Clinical trials, such as the SELF-CERV study, have demonstrated the Teal Wand’s ease of use and accuracy. The study, involving over 600 participants, found that over 98% of participants collected a valid sample, with 95% of results aligning with those obtained from clinician-collected samples. Additionally, 93% of participants found the device easy to use, and 94% preferred it over clinician-collected samples.

The availability of at-home self-collection aims to broaden the reach of cervical cancer screening, particularly among individuals who face barriers such as transportation limitations, time constraints, or discomfort with speculum exams.

Teal Health plans to launch the Teal Wand in California in June 2025, with hopes of expanding to other states. A prescription is required for the test, and the company will offer a telehealth option. Self-collection is not recommended for individuals who are pregnant, have a history of cervical precancer treatment, are HIV-positive or immunocompromised, or have a history of reproductive system cancer.